Bicalutamide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bicalutamide" in Italian language version.

refsWebsite

Global rank Italian rank

14web.archive.org

1^st place

12books.google.com

3^rd place

14^th place

10doi.org

2^nd place

7^th place

10nih.gov

4^th place

9^th place

8oadoi.org

799^th place

22^nd place

2drugs.com

399^th place

1,563^rd place

2fda.gov

447^th place

644^th place

1sigmaaldrich.com

924^th place

2,349^th place

1who.int

195^th place

342^nd place

1uab.cat

6,782^nd place

low place

1fool.com

4,183^rd place

4,832^nd place

books.google.com

Richard C. Dart, Medical Toxicology, Lippincott Williams & Wilkins, 2004, pp. 497, 521, ISBN 978-0-7817-2845-4 (archiviato l'11 maggio 2016).
Thomas L. Lemke e David A. Williams, Foye's Principles of Medicinal Chemistry, Lippincott Williams & Wilkins, 2008, pp. 121, 1288, 1290, ISBN 978-0-7817-6879-5 (archiviato l'8 settembre 2017).
Linda Skidmore-Roth, Mosby's 2014 Nursing Drug Reference – Elsevieron VitalSource, Elsevier Health Sciences, 17 aprile 2013, pp. 193–194, ISBN 978-0-323-22267-9.
Virgil Craig Jordan e B. J. A. Furr, Hormone Therapy in Breast and Prostate Cancer, Springer Science & Business Media, 5 febbraio 2010, pp. 350–, ISBN 978-1-59259-152-7 (archiviato il 29 maggio 2016).
John A.H. Wass e Paul M. Stewart, Oxford Textbook of Endocrinology and Diabetes, OUP Oxford, 28 luglio 2011, pp. 1625–, ISBN 978-0-19-923529-2 (archiviato l'11 maggio 2016).
(EN) Iqbal Shergill, Manit Arya, Philippe R. Grange e A. R. Mundy, Medical Therapy in Urology, Springer Science & Business Media, 2010, p. 40, ISBN 978-1-84882-704-2 (archiviato il 28 ottobre 2014).
Hywel Williams, Michael Bigby, Thomas Diepgen, Andrew Herxheimer, Luigi Naldi e Berthold Rzany, Evidence-Based Dermatology, John Wiley & Sons, 22 gennaio 2009, pp. 529–, ISBN 978-1-4443-0017-8 (archiviato il 2 maggio 2016).
J. Larry Jameson e Leslie J. De Groot, Edndocrinology: Adult and Pediatric, Elsevier Health Sciences, 25 febbraio 2015, pp. 2425–2426, 2139, ISBN 978-0-323-32195-2.
Jerry Shapiro, Hair Disorders: Current Concepts in Pathophysiology, Diagnosis and Management, An Issue of Dermatologic Clinics, Elsevier Health Sciences, 12 novembre 2012, pp. 187–, ISBN 1-4557-7169-4.
Jerome F. Strauss III e Robert L. Barbieri, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, Elsevier Health Sciences, 28 agosto 2013, pp. 688–, ISBN 978-1-4557-5972-9.
«Bone density improves in men receiving bicalutamide, most likely secondary to the 146% increase in estradiol and the fact that estradiol is the major mediator of bone density in men.»
Robert Marcus, David Feldman, Dorothy Nelson e Clifford J. Rosen, Osteoporosis, Academic Press, 8 novembre 2007, pp. 1354–, ISBN 978-0-08-055347-4 (archiviato l'11 giugno 2016).
(EN) Janos Fischer e C. Robin Ganellin, Analogue-based Drug Discovery, John Wiley & Sons, 2006, p. 515, ISBN 978-3-527-60749-5.

doi.org

dx.doi.org

Cockshott ID, Bicalutamide: clinical pharmacokinetics and metabolism, in Clinical Pharmacokinetics, vol. 43, n. 13, 2004, pp. 855–878, DOI:10.2165/00003088-200443130-00003, PMID 15509184.
«These data indicate that direct glucuronidation is the main metabolic pathway for the rapidly cleared (S)-bicalutamide, whereas hydroxylation followed by glucuronidation is a major metabolic pathway for the slowly cleared (R)-bicalutamide.»
Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O, Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme, in Basic & Clinical Pharmacology & Toxicology, vol. 113, n. 2, August 2013, pp. 92–102, DOI:10.1111/bcpt.12071, PMC 3815647, PMID 23527766.
Yuan J, Desouza R, Westney OL, Wang R, Insights of priapism mechanism and rationale treatment for recurrent priapism, in Asian Journal of Andrology, vol. 10, n. 1, 2008, pp. 88–101, DOI:10.1111/j.1745-7262.2008.00314.x, PMID 18087648.
LJ Gooren, Clinical practice. Care of transsexual persons., in The New England Journal of Medicine, vol. 364, n. 13, 31 marzo 2011, pp. 1251–7, DOI:10.1056/nejmcp1008161, PMID 21449788.
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life, in The Journal of Sexual Medicine, vol. 7, n. 9, 2010, pp. 2996–3010, DOI:10.1111/j.1743-6109.2010.01902.x, PMID 20626600.
Wellington K, Keam SJ, Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer (PDF), in Drugs, vol. 66, n. 6, 2006, pp. 837–50, DOI:10.2165/00003495-200666060-00007, PMID 16706554. URL consultato il 15 settembre 2017 (archiviato dall'url originale il 28 agosto 2016).
Singh SM, Gauthier S, Labrie F, Androgen receptor antagonists (antiandrogens): structure-activity relationships, in Current Medicinal Chemistry, vol. 7, n. 2, February 2000, pp. 211–47, DOI:10.2174/0929867003375371, PMID 10637363.
Mahler C, Verhelst J, Denis L, Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer, in Clinical Pharmacokinetics, vol. 34, n. 5, May 1998, pp. 405–17, DOI:10.2165/00003088-199834050-00005, PMID 9592622.
Mukherji D, Pezaro CJ, De-Bono JS, MDV3100 for the treatment of prostate cancer, in Expert Opinion on Investigational Drugs, vol. 21, n. 2, February 2012, pp. 227–33, DOI:10.1517/13543784.2012.651125, PMID 22229405.
Dmitri Pchejetski, Heba Alshaker e Justin Stebbing, Castrate-resistant prostate cancer: the future of antiandrogens, in Trends in Urology & Men's Health, vol. 5, n. 1, 2014, pp. 7–10, DOI:10.1002/tre.371.

drugs.com

Bicalutamide, su drugs.com, The American Society of Health-System Pharmacists. URL consultato l'8 dicembre 2016 (archiviato il 29 dicembre 2016).
Bicalutamide – International Drug Names, su drugs.com. URL consultato il 13 agosto 2016 (archiviato il 18 settembre 2016).

fda.gov

accessdata.fda.gov

Casodex® (bicalutamide) Tablets (PDF), su accessdata.fda.gov, FDA (archiviato il 27 febbraio 2017).

fda.gov

Stephen Chang, Bicalutamide BPCA Drug Use Review in the Pediatric Population (PDF), U.S. Department of Health and Human Service, 10 marzo 2010. URL consultato il 20 luglio 2016 (archiviato il 24 ottobre 2016).

fool.com

Todd Campbell, Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation, su fool.com, The Motley Fool, 22 gennaio 2014. URL consultato il 20 luglio 2016 (archiviato il 26 agosto 2016).
«[...] the most commonly prescribed treatment for metastatic castration resistant prostate cancer: bicalutamide. That was sold as AstraZeneca's billion-dollar-a-year drug Casodex before losing patent protection in 2008. AstraZeneca still generates a few hundred million dollars in sales from Casodex, [...]»

nih.gov

ncbi.nlm.nih.gov

Cockshott ID, Bicalutamide: clinical pharmacokinetics and metabolism, in Clinical Pharmacokinetics, vol. 43, n. 13, 2004, pp. 855–878, DOI:10.2165/00003088-200443130-00003, PMID 15509184.
«These data indicate that direct glucuronidation is the main metabolic pathway for the rapidly cleared (S)-bicalutamide, whereas hydroxylation followed by glucuronidation is a major metabolic pathway for the slowly cleared (R)-bicalutamide.»
Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O, Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme, in Basic & Clinical Pharmacology & Toxicology, vol. 113, n. 2, August 2013, pp. 92–102, DOI:10.1111/bcpt.12071, PMC 3815647, PMID 23527766.
Yuan J, Desouza R, Westney OL, Wang R, Insights of priapism mechanism and rationale treatment for recurrent priapism, in Asian Journal of Andrology, vol. 10, n. 1, 2008, pp. 88–101, DOI:10.1111/j.1745-7262.2008.00314.x, PMID 18087648.
LJ Gooren, Clinical practice. Care of transsexual persons., in The New England Journal of Medicine, vol. 364, n. 13, 31 marzo 2011, pp. 1251–7, DOI:10.1056/nejmcp1008161, PMID 21449788.
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life, in The Journal of Sexual Medicine, vol. 7, n. 9, 2010, pp. 2996–3010, DOI:10.1111/j.1743-6109.2010.01902.x, PMID 20626600.
Wellington K, Keam SJ, Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer (PDF), in Drugs, vol. 66, n. 6, 2006, pp. 837–50, DOI:10.2165/00003495-200666060-00007, PMID 16706554. URL consultato il 15 settembre 2017 (archiviato dall'url originale il 28 agosto 2016).
Singh SM, Gauthier S, Labrie F, Androgen receptor antagonists (antiandrogens): structure-activity relationships, in Current Medicinal Chemistry, vol. 7, n. 2, February 2000, pp. 211–47, DOI:10.2174/0929867003375371, PMID 10637363.
Mahler C, Verhelst J, Denis L, Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer, in Clinical Pharmacokinetics, vol. 34, n. 5, May 1998, pp. 405–17, DOI:10.2165/00003088-199834050-00005, PMID 9592622.
(JA) Akaza H, [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer—basic clinical aspects], in Gan to Kagaku Ryoho. Cancer & Chemotherapy, vol. 26, n. 8, 1999, pp. 1201–7, PMID 10431591.
Mukherji D, Pezaro CJ, De-Bono JS, MDV3100 for the treatment of prostate cancer, in Expert Opinion on Investigational Drugs, vol. 21, n. 2, February 2012, pp. 227–33, DOI:10.1517/13543784.2012.651125, PMID 22229405.

oadoi.org

Cockshott ID, Bicalutamide: clinical pharmacokinetics and metabolism, in Clinical Pharmacokinetics, vol. 43, n. 13, 2004, pp. 855–878, DOI:10.2165/00003088-200443130-00003, PMID 15509184.
«These data indicate that direct glucuronidation is the main metabolic pathway for the rapidly cleared (S)-bicalutamide, whereas hydroxylation followed by glucuronidation is a major metabolic pathway for the slowly cleared (R)-bicalutamide.»
Yuan J, Desouza R, Westney OL, Wang R, Insights of priapism mechanism and rationale treatment for recurrent priapism, in Asian Journal of Andrology, vol. 10, n. 1, 2008, pp. 88–101, DOI:10.1111/j.1745-7262.2008.00314.x, PMID 18087648.
LJ Gooren, Clinical practice. Care of transsexual persons., in The New England Journal of Medicine, vol. 364, n. 13, 31 marzo 2011, pp. 1251–7, DOI:10.1056/nejmcp1008161, PMID 21449788.
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life, in The Journal of Sexual Medicine, vol. 7, n. 9, 2010, pp. 2996–3010, DOI:10.1111/j.1743-6109.2010.01902.x, PMID 20626600.
Singh SM, Gauthier S, Labrie F, Androgen receptor antagonists (antiandrogens): structure-activity relationships, in Current Medicinal Chemistry, vol. 7, n. 2, February 2000, pp. 211–47, DOI:10.2174/0929867003375371, PMID 10637363.
Mahler C, Verhelst J, Denis L, Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer, in Clinical Pharmacokinetics, vol. 34, n. 5, May 1998, pp. 405–17, DOI:10.2165/00003088-199834050-00005, PMID 9592622.
Mukherji D, Pezaro CJ, De-Bono JS, MDV3100 for the treatment of prostate cancer, in Expert Opinion on Investigational Drugs, vol. 21, n. 2, February 2012, pp. 227–33, DOI:10.1517/13543784.2012.651125, PMID 22229405.
Dmitri Pchejetski, Heba Alshaker e Justin Stebbing, Castrate-resistant prostate cancer: the future of antiandrogens, in Trends in Urology & Men's Health, vol. 5, n. 1, 2014, pp. 7–10, DOI:10.1002/tre.371.

sigmaaldrich.com

Bicalutamide (CDX) ≥98% (HPLC), powder, su sigmaaldrich.com, Sigma-Aldrich. URL consultato il 15 settembre 2017.

uab.cat

ddd.uab.cat

1999 Annual Report and Form 20-F (PDF), su ddd.uab.cat, AstraZeneca. URL consultato il 1º luglio 2017.

web.archive.org

Richard C. Dart, Medical Toxicology, Lippincott Williams & Wilkins, 2004, pp. 497, 521, ISBN 978-0-7817-2845-4 (archiviato l'11 maggio 2016).
Thomas L. Lemke e David A. Williams, Foye's Principles of Medicinal Chemistry, Lippincott Williams & Wilkins, 2008, pp. 121, 1288, 1290, ISBN 978-0-7817-6879-5 (archiviato l'8 settembre 2017).
Virgil Craig Jordan e B. J. A. Furr, Hormone Therapy in Breast and Prostate Cancer, Springer Science & Business Media, 5 febbraio 2010, pp. 350–, ISBN 978-1-59259-152-7 (archiviato il 29 maggio 2016).
Bicalutamide, su drugs.com, The American Society of Health-System Pharmacists. URL consultato l'8 dicembre 2016 (archiviato il 29 dicembre 2016).
John A.H. Wass e Paul M. Stewart, Oxford Textbook of Endocrinology and Diabetes, OUP Oxford, 28 luglio 2011, pp. 1625–, ISBN 978-0-19-923529-2 (archiviato l'11 maggio 2016).
(EN) Iqbal Shergill, Manit Arya, Philippe R. Grange e A. R. Mundy, Medical Therapy in Urology, Springer Science & Business Media, 2010, p. 40, ISBN 978-1-84882-704-2 (archiviato il 28 ottobre 2014).
Hywel Williams, Michael Bigby, Thomas Diepgen, Andrew Herxheimer, Luigi Naldi e Berthold Rzany, Evidence-Based Dermatology, John Wiley & Sons, 22 gennaio 2009, pp. 529–, ISBN 978-1-4443-0017-8 (archiviato il 2 maggio 2016).
Casodex® (bicalutamide) Tablets (PDF), su accessdata.fda.gov, FDA (archiviato il 27 febbraio 2017).
Wellington K, Keam SJ, Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer (PDF), in Drugs, vol. 66, n. 6, 2006, pp. 837–50, DOI:10.2165/00003495-200666060-00007, PMID 16706554. URL consultato il 15 settembre 2017 (archiviato dall'url originale il 28 agosto 2016).
Robert Marcus, David Feldman, Dorothy Nelson e Clifford J. Rosen, Osteoporosis, Academic Press, 8 novembre 2007, pp. 1354–, ISBN 978-0-08-055347-4 (archiviato l'11 giugno 2016).
WHO Model List of Essential Medicines (19th List), su World Health Organization, April 2015. URL consultato l'8 dicembre 2016 (archiviato il 13 dicembre 2016).
Bicalutamide – International Drug Names, su drugs.com. URL consultato il 13 agosto 2016 (archiviato il 18 settembre 2016).
Todd Campbell, Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation, su fool.com, The Motley Fool, 22 gennaio 2014. URL consultato il 20 luglio 2016 (archiviato il 26 agosto 2016).
«[...] the most commonly prescribed treatment for metastatic castration resistant prostate cancer: bicalutamide. That was sold as AstraZeneca's billion-dollar-a-year drug Casodex before losing patent protection in 2008. AstraZeneca still generates a few hundred million dollars in sales from Casodex, [...]»
Stephen Chang, Bicalutamide BPCA Drug Use Review in the Pediatric Population (PDF), U.S. Department of Health and Human Service, 10 marzo 2010. URL consultato il 20 luglio 2016 (archiviato il 24 ottobre 2016).

who.int

WHO Model List of Essential Medicines (19th List), su World Health Organization, April 2015. URL consultato l'8 dicembre 2016 (archiviato il 13 dicembre 2016).